Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (252)	4/3/2001 8:31:22 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 395

Repligen to Report Initial Results of Phase 2 Clinical Trial Conference Call and Web Cast Invitation NEEDHAM, Mass., April 3 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN - news) announced today that the Company President and Chief Executive Officer Dr. Walter C. Herlihy will host a conference call on Wednesday April 4, 2001 to report the initial results of the Phase 2 Clinical Trial of Secretin in Autism. Please access the call at 8:55 a.m. EST on Wednesday April 4, 2001 via the internet at vcall.com or via the Repligen web site at www.repligen.com. If you are unable to access the webcast via the internet, you can also listen to the broadcast by calling 1-800-289-0462. To listen to the webcast via the internet, please go to the web site at least fifteen minutes early to register, download, and if necessary install Real Player audio software. For those who cannot listen to the live broadcast, a replay will be available shortly after the call on the Company's web site at www.repligen.com for 90 days. Repligen Corporation develops new drugs for debilitating pediatric disorders including autism, cancer, and immune and metabolic disorders. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies. Its corporate headquarters are located at 117 Fourth Avenue, Needham MA, 02494. Additional information may be requested from www.repligen.com.